Psychosis



Smartphone Applications Youth With Early Psychosis in Community Outpatient Settings


Conditions:   Psychosis;   Clinical High Risk for Psychosis
Intervention:   Other: Mobi mHealth app
Sponsor:   University of California, Davis
Completed


Guided Dose Reduction of Antipsychotic in Patients With Psychosis in Remitted States


Conditions:   Psychosis;   Remission
Intervention:  
Sponsor:   National Taiwan University Hospital
Recruiting


Early Intervention Psychosis Communication and Engagement Trial


Condition:   First Episode Psychosis
Interventions:   Other: Digital communication;   Other: Non digital
Sponsor:   South London and Maudsley NHS Foundation Trust
Recruiting


IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2


Conditions:   Psychosis;   Autoimmune Encephalitis
Interventions:   Drug: Intravenous immunoglobulin;   Drug: Placebo;   Drug: Rituximab
Sponsors:   University of Cambridge;   University of Oxford
Not yet recruiting


The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study


Condition:   Parkinson Disease Psychosis
Intervention:   Other: Real-world, non-interventional
Sponsor:   ACADIA Pharmaceuticals Inc.
Recruiting


Reducing the Duration of Untreated Psychosis


Condition:   First Episode Psychosis
Intervention:   Other: Community Campaign La CLAVE
Sponsors:   University of Southern California;   University of California, Los Angeles;   National Institute of Mental Health (NIMH)
Recruiting


Is Cognitive Training Neuroprotective in Early Psychosis?


Conditions:   Psychosis;   Healthy
Interventions:   Device: Magnetic Resonance Imaging;   Behavioral: Treatment as Usual;   Behavioral: Targeted Cognitive Training;   Other: Healthy Controls
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   National Institutes of Health (NIH)
Recruiting


A Study of MP-101 in the Treatment of Psychosis in Alzheimer's Disease


Conditions:   Psychosis;   Alzheimer Disease
Interventions:   Drug: MP-101;   Drug: Placebo
Sponsor:   Mediti Pharma Inc.
Recruiting


A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis


Condition:   Parkinson Disease Psychosis
Interventions:   Drug: SEP-363856;   Drug: Placebo capsule
Sponsor:   Sunovion
Recruiting


COllaborative Shared Care to IMprove Psychosis Outcome


Condition:   Psychosis
Intervention:   Behavioral: Collaborative shared care
Sponsor:   University of Ibadan
Recruiting


Expanded Access of Pimavanserin for Patients With PD Psychosis


Condition:   Parkinson's Disease Psychosis
Intervention:   Drug: Pimavanserin tartrate
Sponsor:   ACADIA Pharmaceuticals Inc.
Approved for marketing


Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe


Condition:   Ultra High Risk for Psychosis
Interventions:   Drug: Omega-3 fatty acids;   Other: Placebo
Sponsor:   Rene Kahn
Recruiting


Gabapentin in Patients at Clinical Risk for Psychosis


Condition:   Clinical High Risk for Psychosis
Interventions:   Drug: Gabapentin;   Drug: Placebo
Sponsor:   New York State Psychiatric Institute
Recruiting


Adaptation of Cognitive Enhancement Therapy for Persons at Clinical High Risk for Psychosis


Condition:   Psychosis
Interventions:   Behavioral: CLUES;   Behavioral: therapy and computer games
Sponsors:   Beth Israel Deaconess Medical Center;   National Institute of Mental Health (NIMH)
Recruiting


A Study of the Effectiveness of Cognitive Adaptation Training in Early Intervention for Psychosis


Condition:   Psychosis
Interventions:   Behavioral: Cognitive Adaptation Training;   Behavioral: Action Based Cognitive Remediation
Sponsor:   Centre for Addiction and Mental Health
Active, not recruiting


Culturally Adapted Cognitive Behavior Therapy for Psychosis in Pakistan


Condition:   Psychosis
Intervention:   Behavioral: Culturally Adapted Cognitive behavior therapy
Sponsors:   Pakistan Institute of Learning and Living;   University of Manchester;   Dow University of Health Sciences;   Abbasi Shaheed Hospital
Completed


Exercise and Markers of Medial Temporal Health in Youth At-risk for Psychosis


Condition:   Attenuated Psychosis Syndrome
Interventions:   Behavioral: Exercise 1;   Behavioral: Exercise 2
Sponsors:   University of Colorado, Boulder;   University of Colorado, Denver;   National Institute of Mental Health (NIMH);   Northwestern University
Recruiting


Transcranial Direct Current Stimulation and Cognitive Remediation Therapy for Psychosis


Condition:   Psychosis
Intervention:   Device: tDCS
Sponsor:   University of Minnesota - Clinical and Translational Science Institute
Not yet recruiting


Economic and Clinical Outcomes of Attendance in Psychosis Services Using SMS.


Condition:   Psychosis
Intervention:   Other: SMS reminder
Sponsor:   King's College London
Unknown status


First Episode Psychosis and Pathway to Care in Nordland


Condition:   First Episode Psychosis
Intervention:  
Sponsor:   Nordlandssykehuset HF
Active, not recruiting


N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis


Condition:   Schizophrenic Psychoses
Interventions:   Drug: n-acetylcysteine;   Drug: Placebo
Sponsors:   Beth Israel Deaconess Medical Center;   Center de Neurosciences Psychiatrique, Lausanne, Switzerland
Completed


An Acceptability Study of Unflavored Asenapine Versus Raspberry Flavored Asenapine in Stable Patients With a Psychotic Disorder (P07010)(COMPLETED)


Condition:   Psychosis
Interventions:   Drug: Asenapine WHITE raspberry flavor (Treatment A);   Drug: Asenapine RED raspberry flavor (Treatment B);   Drug: Asenapine WHITE UNFLAVORED (Treatment C)
Sponsor:   Merck Sharp & Dohme Corp.
Completed


Ziprasidone in the Psychosis Prodrome


Condition:   Psychosis Prodrome
Interventions:   Drug: ziprasidone;   Drug: placebo
Sponsor:   Yale University
Completed


A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis


Condition:   Parkinson's Disease Psychosis
Intervention:   Drug: Pimavanserin tartrate (ACP-103)
Sponsor:   ACADIA Pharmaceuticals Inc.
Active, not recruiting


A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis


Condition:   Parkinson's Disease Psychosis
Interventions:   Drug: Pimavanserin tartrate (ACP-103);   Drug: Placebo
Sponsor:   ACADIA Pharmaceuticals Inc.
Completed

Refine Your Search Advanced Search